Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 833-841

  Liu, Juan Juan ^a   Lin, Bei ^a   Hao, Ying Ying ^a   Li, Fei Fei ^a   Liu, Da Wo ^a   Qi, Yue ^a   Zhu, Lian Cheng ^a   Zhang, Shu Lan ^a   Iwamori, Masao ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b KINKI UNIVERSITY   (Japan)

Author keywords

1,2 fucosyltransferase; Epidermal growth factor receptor; Lewis(y) antigen; Ovarian cancer cell line; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUCOSYLTRANSFERASE; GEFITINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P27;

ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER CELL; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVONOIDS; FUCOSYLTRANSFERASES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MORPHOLINES; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77349093763     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000705     Document Type: Article

References (46)

1. Roseman S: Reflections on glycobiology. J Biol Chem 276: 41527-41542, 2001.
2. Nakagoe T, Fukushima K, Itoyanagi N, et al: Expression of ABH/ Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 128: 257-264, 2002.
3. Tsuboi K, Asao T, Ide M, et al: Alpha1,2-fucosylation is a superior predictor of postoperative prognosis for colorectal cancer compared with blood group A, B, or sialyl Lewis X antigen generated within colorectal tumor tissue. Ann Surg Oncol 14: 1880-1889, 2007.
4. Hokke CH, Neeleman AP, Koeleman CA and van den Eijinden DH: Identification of an alpha3-fucosyltransferase and a novel alpha2- fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: biosynthesis of the Fucalpha1 →2Fucalpha1 →3[Gal(NAc)beta1 →4] GlcNAc sequence. Glycobiology 8: 393-406, 1998.
5. Kitamura K, Stockert E, Garin-Chesa P, et al: Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA 91: 12957-12961, 1994.
6. Dettke M, Pálfi G and Loibner H: Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol 68: 511-514, 2000.
7. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: R780-R787, 2005.
8. Arai Y and Nishida M: Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody. Int J Gynecol Cancer 13: 42-46, 2003.
9. Kim YS, Yuan M, Itzkowitz SH, et al: Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and non-malignant colonic tissues. Cancer Res 46: 5985-5992, 1986.
10. Yin BW, Finstad CL, Kitamura K, et al: Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int J Cancer 65: 406-412, 1996.
11. Iwamori M, Tanaka K, Kubushiro K, et al: Alterations in the glyolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,2-fucosyltransferase gene. Cancer Sci 96: 26-30, 2005.
12. Zhao Y, Lin B, Hao YY, et al: The effects of Lewis(y) antigen content on drug resistance to carboplatin in ovarian cancer line RMG-I. Prog Biochem Biophys 35: 1175-1182, 2008.
13. Klinger M, Farhan H, Just H, et al: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 64: 1087-1093, 2004.
14. Farhan H, Schuster C, Klinger M, et al: Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther 319: 1459-1466, 2006.
15. Wang XQ, Sun P, O'Gorman M, Tai T and Paller AS: Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppression [correction of suppression] of activation. Glycobiology 11: 515-522, 2001.
16. Wang X, Zhang S, MacLennan GT, et al: Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 13: 953-957, 2007.
17. Rudd PM and Dwek RA: Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32: 1-100, 1997.
18. Mann M and Jensen ON: Proteomic analysis of post-translational modifications. Nat Biotechnol 21: 255-261, 2003.
19. Rebbaa A, Yamamoto H, Saito T, et al: Gene transfectionmediated overexpression of ß1,4-N-acetylglucosamine-bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function. J Biol Chem 272: 9275-9279, 1997.
20. Guo HB, Jiang AL, Ju TZ and Chen HL: Opposing changes in N-acetylglucosaminyltransferase-V and III during the cell cycle and all-trans retinoic acid treatment of hepatocarcinoma cell line. Biochim Biophys Acta 1495: 297-307, 2000.
21. Hynes NE and MacDonald G: Erb receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 185-193, 2009.
22. Zimmer S, Kahl P, Buhl TM, et al: Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 135: 723-730, 2009.
23. Lopez-Gines C, Gil-Benso R, Benito R, et al: The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 28: 507-515, 2008.
24. Chambard JC, Lefloch R, Pouysségur J and Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta 1773: 1299-1310, 2007.
25. Farley J, Ozbun L, Samimi G and Birrer MJ: Cell cycle and related protein. Dis Markers 23: 433-443, 2007.
26. Nakayama KI, Hatakeyama S and Nakayama K: Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 5: 109-129, 2001.
27. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K and Keyomarsi K: Cyclin E-associated kinase activity predicts response to platinumbased chemotherapy. Clin Cancer Res 13: 4800-4806, 2007.
28. He G, Kuang J, Huang Z, et al: Upregulation of p27 and its inhibitor of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 95: 1514-1524, 2006.
29. Wu H, Goel V and Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122, 2003.
30. Nakao T, Geddis AE, Fox NE and Kaushansky K: PI3K/ Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7: 257-266, 2008.
31. Pai T, Chen Q, Zhang Y, Zolfaqhari R and Ross AC: Galactomutarotase and other galactose-related genes are rapidly induced by retinoic acid in human myeloid cells. Biochemistry 46: 15198-15207, 2007.
32. Aamoudse CA, Bax M, Sánchez-Hernández M, García-Vallejo JJ and van Koovk Y: Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int J Cancer 122: 839-846, 2008.
33. Nonaka M, Ma BY, Murai R, et al: Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumorassociated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol 180: 3347-3356, 2008.
34. Federici MF, Kudryashov V, Saigo PE, Finstad CL and Lloyd KO: Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer 81: 193-198, 1999.
35. Li FF, Lin B, Hao YY, Liu JJ, Zhang F and Zhang SL: Inhibitory effect of anti-Lewis y antibody on alpha1,2-fucosyltransferase gene transfected human ovarian cancer cells in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24: 267-269, 2008.
36. Zhu LC, Lin B, Hao YY, Li FF, Diao B and Zhang SL: Impact of alpha1,2-fucosyltransferase gene transfection on cancer related gene expression profile of human ovarian cancer cell line RMG-I. Ai Zheng 27: 934-941, 2008.
37. Chrysogelos SA and Dickson RB: EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29: 29-40, 1994.
38. McKenna WG, Muschel RJ, Gupta AK, Hahn SM and Bernhard EJ: The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22: 5866-5875, 2003.
39. Goel S, Hidalgo M and Perez-Soler R: EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 6: 305-320, 2007.
40. Shukala S, Maclennan GT, Marengo SR, Resnick MI and Gupta S: Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64: 224-239, 2005.
41. Tan X, Eqami H, Abe M, Nozawa F, Hirota M and Qqawa M: Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol 58: 1242-1248, 2005.
42. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L and Das M: Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res 47: 2531-2536, 1987.
43. Medeu H, Marx D, Roeggleu T, Schauer A and Kulu W: Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 17: 61-65, 1998.
44. Verri E, Guglielmini P, Puntoni M, et al: HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 68: 154-161, 2005.
45. Tzahar E and Yarden Y: The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377: M25-M37, 1998.
46. Zandi R, Larsen AB, Andersen P, Stockhausen MT and Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19: 2013-2023, 2007.